{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:20:54Z","timestamp":1783182054955,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,4]]},"DOI":"10.7759\/cureus.112042","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:04:37Z","timestamp":1783181077000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapy-Associated Vitiligo: Hypopigmentation Secondary to Programmed Cell Death Protein 1 Inhibitors, Interferon Alfa-2b, Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors, and B-Raf\/Mitogen-Activated Protein Kinase Kinase Inhibitors"],"prefix":"10.7759","author":[{"given":"Kritin K","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeya","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Beckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Olagbenro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floyd A","family":"Pirtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Posligua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sancy A","family":"Leachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis","volume":"11","author":"Ali Z","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013, 11:81-91. 10.1016\/j.ejcsup.2013.07.012","journal-title":"EJC Suppl"},{"key":"ref2","unstructured":"Aim at Melanoma Foundation. 2023 melanoma facts & statistics. (2023). Accessed: September 6, 2025: https:\/\/www.aimatmelanoma.org\/facts-statistics\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli ML","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020, 38:621-48. 10.1146\/annurev-immunol-100919-023531","journal-title":"Annu Rev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2025.02.012","article-title":"Vitiligo and melanoma: revisiting a historic relationship through a retrospective case-control investigation","volume":"43","author":"Verma KK","year":"2025","unstructured":"Verma KK, Chaudhury H, Chaudhury T, et al.. Vitiligo and melanoma: revisiting a historic relationship through a retrospective case-control investigation. Clin Dermatol. 2025, 43:407-9. 10.1016\/j.clindermatol.2025.02.012","journal-title":"Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich FF","year":"2020","unstructured":"Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J Clin Med. 2020, 9:10.3390\/jcm9010223","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156113","article-title":"Interferon alpha-2b (IFN\u03b12b) in precision oncology: Innovations in delivery and combinatorial immunotherapy","volume":"273","author":"Bindu S","year":"2025","unstructured":"Bindu S, Ash A, Sarkar K. Interferon alpha-2b (IFN\u03b12b) in precision oncology: Innovations in delivery and combinatorial immunotherapy. Pathol Res Pract. 2025, 273:156113. 10.1016\/j.prp.2025.156113","journal-title":"Pathol Res Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02776","article-title":"Long-term follow-up of real-world adjuvant anti-PD-1 checkpoint inhibition and targeted therapy in patients with stage III melanoma","volume":"43","author":"Lodde GC","year":"2025","unstructured":"Lodde GC, Hassel JC, von Wasielewski I, et al.. Long-term follow-up of real-world adjuvant anti-PD-1 checkpoint inhibition and targeted therapy in patients with stage III melanoma. J Clin Oncol. 2025, 43:2793-805. 10.1200\/JCO-24-02776","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-019-0096-8","article-title":"A review of immune-mediated adverse events in melanoma","volume":"7","author":"Kennedy LB","year":"2019","unstructured":"Kennedy LB, Salama AK. A review of immune-mediated adverse events in melanoma. Oncol Ther. 2019, 7:101-20. 10.1007\/s40487-019-0096-8","journal-title":"Oncol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch9","article-title":"Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application","author":"Rausch MP","year":"2017","unstructured":"Rausch MP, Hastings KT. Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. Ward WH, Farma JM (ed): Codon Publications, Brisbane, Australia; 2017. 10.15586\/codon.cutaneousmelanoma.2017.ch9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23251","article-title":"Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion","volume":"112","author":"Hauschild A","year":"2008","unstructured":"Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dr\u00e9no B, Kirkwood JM. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008, 112:982-94. 10.1002\/cncr.23251","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2025.151903","article-title":"Acceptability of an electronic patient-reported outcomes-based model of care to monitor symptoms related to cancer treatment with immune checkpoint inhibitors: results from the Iepro randomized controlled trial","volume":"41","author":"Lopes AM","year":"2025","unstructured":"Lopes AM, Giacomini S, Ulahannan A, et al.. Acceptability of an electronic patient-reported outcomes-based model of care to monitor symptoms related to cancer treatment with immune checkpoint inhibitors: results from the Iepro randomized controlled trial. Semin Oncol Nurs. 2025, 41:151903. 10.1016\/j.soncn.2025.151903","journal-title":"Semin Oncol Nurs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701044","article-title":"Inhibitors of the PD-1 pathway in tumor therapy","volume":"200","author":"LaFleur MW","year":"2018","unstructured":"LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 2018, 200:375-83. 10.4049\/jimmunol.1701044","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu R","year":"2024","unstructured":"Liu R, Li HF, Li S. PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy. Cell Insight. 2024, 3:100146. 10.1016\/j.cellin.2024.100146","journal-title":"Cell Insight"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/970315","article-title":"Human interferon alpha-2b: a therapeutic protein for cancer treatment","volume":"2014","author":"Asmana Ningrum R","year":"2014","unstructured":"Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014, 2014:970315. 10.1155\/2014\/970315","journal-title":"Scientifica (Cairo)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2020.0231","article-title":"IFN-\u03b1-2b inhibits the proliferation and migration of fibroblasts via the TGF\u03b2\/smad signaling pathway to reduce postoperative epidural fibrosis","volume":"41","author":"Liu Z","year":"2021","unstructured":"Liu Z, Chen H, Fan Z, et al.. IFN-\u03b1-2b inhibits the proliferation and migration of fibroblasts via the TGF\u03b2\/smad signaling pathway to reduce postoperative epidural fibrosis. J Interferon Cytokine Res. 2021, 41:271-82. 10.1089\/jir.2020.0231","journal-title":"J Interferon Cytokine Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar GS","year":"2010","unstructured":"Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010, 80:624-37. 10.1016\/j.bcp.2010.04.029","journal-title":"Biochem Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153754","article-title":"Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis","volume":"15","author":"Priantti JN","year":"2023","unstructured":"Priantti JN, Vilbert M, Madeira T, Moraes FC, Hein EC, Saeed A, Cavalcante L. Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023, 15:10.3390\/cancers15153754","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick DT","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP, et al.. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013, 19:1225-31. 10.1158\/1078-0432.CCR-12-1630","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/82_2017_61","article-title":"CTLA-4, an essential immune-checkpoint for T-cell activation","volume":"410","author":"Chikuma S","year":"2017","unstructured":"Chikuma S. CTLA-4, an essential immune-checkpoint for T-cell activation. Curr Top Microbiol Immunol. 2017, 410:99-126. 10.1007\/82_2017_61","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings HE","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015, 33:773-81. 10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy","volume":"14","author":"Carbone ML","year":"2023","unstructured":"Carbone ML, Capone A, Guercio M, et al.. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy. Front Immunol. 2023, 14:1197630. 10.3389\/fimmu.2023.1197630","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03743-1","article-title":"Psychiatric comorbidities, inflammatory bowel disease, and urticaria in acne vulgaris patients undergoing isotretinoin treatment: a multicenter cohort study from the TriNetX database","volume":"317","author":"Verma KK","year":"2025","unstructured":"Verma KK, Koch RS, Friedmann DP, Tarbox MB, Tyring SK. Psychiatric comorbidities, inflammatory bowel disease, and urticaria in acne vulgaris patients undergoing isotretinoin treatment: a multicenter cohort study from the TriNetX database. Arch Dermatol Res. 2025, 317:183. 10.1007\/s00403-024-03743-1","journal-title":"Arch Dermatol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70299","article-title":"Association of vitiligo with metabolic and cardiovascular comorbidities: a multicenter propensity-matched cohort analysis","volume":"65","author":"Verma KK","year":"2026","unstructured":"Verma KK, Robertson OT, Nguyen KT, et al.. Association of vitiligo with metabolic and cardiovascular comorbidities: a multicenter propensity-matched cohort analysis. Int J Dermatol. 2026, 65:1484-6. 10.1111\/ijd.70299","journal-title":"Int J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485761-therapy-associated-vitiligo-hypopigmentation-secondary-to-programmed-cell-death-protein-1-inhibitors-interferon-alfa-2b-cytotoxic-t-lymphocyte-associated-protein-4-inhibitors-and-b-rafmitogen-activated-protein-kinase-kinase-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:04:39Z","timestamp":1783181079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485761-therapy-associated-vitiligo-hypopigmentation-secondary-to-programmed-cell-death-protein-1-inhibitors-interferon-alfa-2b-cytotoxic-t-lymphocyte-associated-protein-4-inhibitors-and-b-rafmitogen-activated-protein-kinase-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.112042","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,4]]}}}